Quality indicators for the care of osteoporosis in vulnerable elders

Journal of the American Geriatrics Society

Volumn 55, Issue SUPPL. 2, 2007, Pages

  Grossman, Jennifer ^a,b   MacLean, Catherine H ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d Wellpoint Inc   (United States)

Author keywords

Geriatrics; Osteoporosis; Quality of care

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

AGING; ALCOHOL CONSUMPTION; BONE DENSITY; CLINICAL TRIAL; DIETARY INTAKE; DUAL ENERGY X RAY ABSORPTIOMETRY; ELDERLY CARE; EXERCISE; FRACTURE; HEALTH CARE QUALITY; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; META ANALYSIS; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; REVIEW; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; ADRENAL CORTEX HORMONES; AGED; BONE DENSITY CONSERVATION AGENTS; COUNSELING; EVIDENCE-BASED MEDICINE; EXERCISE; FRACTURES, BONE; FRAIL ELDERLY; HUMANS; OSTEOPOROSIS; PROCESS ASSESSMENT (HEALTH CARE); QUALITY INDICATORS, HEALTH CARE;

EID: 34848817375     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01347.x     Document Type: Review

References (166)

1. Christiansen C. Consensus development conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993 94 : 646 650.
2. Lindsay R. Osteoporosis. A Guide to Diagnosis, Prevention and Treatment. New York : Raven Press, 1992.
3. Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997 12 : 24 35.
4. Staats DO, Beier M, Cantrell L et al. Osteoporosis. Clinical Practice Guidelines. Columbia, MD : American Medical Directors Association, 1998.
5. American Association of Clinical Endocrinologists (AACE) Osteoporosis task force. American association of clinical endrocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocrine Pract 2003 9 : 544 564.
6. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC : National Osteoporosis Foundation, 2003.
7. Fractured neck of femur Prevention and management. Summary and recommendations of a report of the royal college of physicians. J R Coll Physicians Lond 1989 23 : 8 12.
8. American Medical Directors Association (AMDA). Osteoporosis. Clinical Practice Guideline. Columbia, MD : American Medical Directors Association, 2003.
9. U.S. Preventive Services Task Force. Clinician's Handbook of Preventive Services, 2nd Ed. [on-line]. Available at Accessed January 11, 1999.
10. Age Charts for Periodic Health Examination. Leawood, KS : American Academy of Family Physicians, 1994.
11. The prevention and management of osteoporosis: Consensus statement. Med J Aust 1997 167 (Suppl) : S1 S15.
12. Josse R, Tenenhouse AM, Hanley DA et al. Clinical practice guidelines for the diagnosis and management of osteoporosis. Can Med Assoc J 1996 155 : 1113 1129.
13. Cheung AM, Feig DS, Kapral M et al. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: Recommendation statement from the Canadian Task Force on Preventive Health Care. Can Med Assoc J 2004 170 : 1665 1667.
14. Kern LM, Powe NR, Levine MA et al. Association between screening for osteoporosis and the incidence of hip fracture. Ann Intern Med 2005 142 : 173 181.
15. Fitt NS, Mitchell SL, Cranney A et al. Influence of bone densitometry results on the treatment of osteoporosis. Can Med Assoc J 2001 164 : 777 781.
16. Solomon DH, Levin E, Helfgott SM. Patterns of medication use before and after bone densitometry: Factors associated with appropriate treatment. J Rheumatol 2000 27 : 1496 1500.
17. Brennan RM, Wactawski-Wende J, Crespo CJ et al. Factors associated with treatment initiation after osteoporosis screening. Am J Epidemiol 2004 160 : 475 483.
18. Papaioannou A, Parkinson W, Adachi J et al. Women's decisions about hormone replacement therapy after education and bone densitometry. Can Med Assoc J 1998 159 : 1253 1257.
19. Torgerson DJ, Thomas RE, Campbell MK et al. Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. Arch Intern Med 1997 157 : 2121 2125.
20. Gardsell P, Johnell O, Nilsson BE et al. Predicting various fragility fractures in women by forearm bone densitometry: A follow-up study. Calcif Tissue Int 1993 52 : 348 353.
21. Ross PD, Wasnich RD, Heilbrun LK et al. Definition of a spine fracture threshold based upon prospective fracture risk. Bone 1987 8 : 271 278.
22. Hui SL, Slemenda CW, Johnston CC Jr. Baseline measurements of bone mass predicts fractures in white women. Ann Intern Med 1989 111 : 355 361.
23. Cummings SR, Black DM, Nevitt MC et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 1990 263 : 665 668.
24. Johnell O, Kanis JA, Oden A et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005 20 : 1185 1194.
25. Nevitt MC, Johnell O, Black DM et al. Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group. Osteoporos Int 1994 4 : 325 331.
26. Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: A review of findings from prospective studies. Am J Med 1995 98 : 24S 28S.
27. Miller PD, McClung M. Prediction of fracture risk. I: Bone density. Am J Med Sci 1996 312 : 257 259.
28. Johnston CC Jr., Slemenda CW, Melton LJ. Clinical use of bone densitometry. N Engl J Med 1991 324 : 1105 1109.
29. Melton LJ, Eddy DM, Johnston CC Jr. Screening for osteoporosis. Ann Intern Med 1990 112 : 516 528.
30. Chandler JM, Zimmerman SI, Girman CJ et al. Low bone mineral density and risk of fracture in white female nursing home residents. JAMA 2000 284 : 972 977.
31. Greenspan SL, Myers ER, Kiel DP et al. Fall direction, bone mineral density, and function: Risk factors for hip fracture in frail nursing home elderly. Am J Med 1998 104 : 539 545.
32. Broe KE, Hannan MT, Kiely DK et al. Predicting fractures using bone mineral density: A prospective study of long-term care residents. Osteoporos Int 2000 11 : 765 771.
33. Position statement: Executive summary. The writing group for the International Society for Clinical Densitometry (ISCD) position development conference. J Clin Densitom 2004 7 : 7 12.
34. Management of Osteoporosis. a National Clinical Guideline. Edinburgh, Scotland : Scottish Intercollegiate Guidelines Network, 2003.
35. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 2002 137 : 526 528.
36. Szulc P, Munoz F, Duboeuf F et al. Bone mineral density predicts osteoporotic fractures in elderly men: The MINOS Study. Osteoporos Int 2005 16 : 1184 1192.
37. Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004 19 : 893 899.
38. Khosla S, Melton J Fracture risk in primary hyperparathyroidism. J Bone Miner Res 2002 17 (Suppl 2) : N103 N107.
39. Cankurtaran M, Yavuz BB, Halil M et al. General characteristics, clinical features and related factors of osteoporosis in a group of elderly Turkish men. Aging Clin Exp Res 2005 17 : 108 115.
40. Kanis JA, Johansson H, Oden A et al. A family history of fracture and fracture risk: A meta-analysis. Bone 2004 35 : 1029 1037.
41. Tanaka T, Latorre MR, Jaime PC et al. Risk factors for proximal femur osteoporosis in men aged 50 years or older. Osteoporos Int 2001 12 : 942 949.
42. Orwoll ES, Bevan L, Phipps KR. Determinants of bone mineral density in older men. Osteoporos Int 2000 11 : 815 821.
43. Jackson JA, Kleerekoper M, Parfitt AM et al. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987 65 : 53 58.
44. Yeh SS, Phanumas D, Hafner A et al. Risk factors for osteoporosis in a subgroup of elderly men in a Veterans Administration nursing home. J Investig Med 2002 50 : 452 457.
45. Patel A, Coates PS, Nelson JB et al. Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis? J Clin Densitom 2003 6 : 323 330.
46. van den Beld AW, de Jong FH, Grobbee DE et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000 85 : 3276 3282.
47. Rapado A, Hawkins F, Sobrinho L et al. Bone mineral density and androgen levels in elderly males. Calcif Tissue Int 1999 65 : 417 421.
48. Amin S, Zhang Y, Sawin CT et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham Study. Ann Intern Med 2000 133 : 951 963.
49. Mittan D, Lee S, Miller E et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002 87 : 3656 3661.
50. Morote J, Martinez E, Trilla E et al. Osteoporosis during continuous androgen deprivation: Influence of the modality and length of treatment. Eur Urol 2003 44 : 661 665.
51. Krupski TL, Smith MR, Lee WC et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004 101 : 541 549.
52. Diamond TH, Bucci J, Kersley JH et al. Osteoporosis and spinal fractures in men with prostate cancer: Risk factors and effects of androgen deprivation therapy. J Urol 2004 172 : 529 532.
53. Kanis JA, Johnell O, De Laet C et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004 35 : 375 382.
54. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 348 : 1535 1541.
55. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001 344 : 333 340.
56. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999 282 : 637 645.
57. Elliot-Gibson V, Bogoch ER, Jamal SA et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: A systematic review. Osteoporos Int 2004 15 : 767 778.
58. The State of Health Care Quality: Industry Trends and Analysis. Washington, DC : National Committee for Quality Assurance, 2005.
59. Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int 2003 14 : 722 727.
60. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000 17 : 1 36.
61. Homik J, Suarez-Almazor M, Shea B et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 1998 (2) : CD000952.
62. Amin S, LaValley MP, Simms RW et al. The role of vitamin D in corticosteroid-induced osteoporosis: A meta-analytic approach. Arthritis Rheum 1999 42 : 1740 1751.
63. Richy F, Ethgen O, Bruyere O et al. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: A meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004 15 : 301 310.
64. Devogelaer JP, Goemaere S, Boonen S et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: A consensus document of the Belgian bone club. Osteoporos Int 2006 17 : 8 19.
65. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001 44 : 1496 1503.
66. Sambrook PN, Diamond T, Ferris L et al. Corticosteroid induced osteoporosis. Guidelines for treatment. Aust Fam Physician 2001 30 : 793 796.
67. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the department of veterans affairs. Arch Intern Med 2003 163 : 2619 2624.
68. Homik J, Cranney A, Shea B et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000 (2) : CD001347.
69. Amin S, Lavalley MP, Simms RW et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: A meta-regression. J Bone Miner Res 2002 17 : 1512 1526.
70. Cortet B, Hachulla E, Barton I et al. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Rev Rheum Engl Ed 1999 66 : 214 219.
71. Sato S, Ohosone Y, Suwa A et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year follow-up. J Rheumatol 2003 30 : 2673 2679.
72. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000 15 : 1006 1013.
73. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999 42 : 2309 2318.
74. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001 44 : 202 211.
75. Nawata H, Soen S, Takayanagi R et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005 23 : 105 109.
76. Jamal SA, Leiter RE, Bayoumi AM et al. Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int 2005 16 : 534 540.
77. Tannenbaum C, Clark J, Schwartzman K et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002 87 : 4431 4437.
78. Wong PK, Spencer DG, McElduff P et al. Secondary screening for osteoporosis in patients admitted with minimal-trauma fracture to a major teaching hospital. Intern Med J 2003 33 : 505 510.
79. Barzel US. Recommended testing in patients with low bone density. J Clin Endocrinol Metab 2003 88 : 1404 1405 author reply 1405.
80. Dennison E, Eastell R, Fall CH et al. Determinants of bone loss in elderly men and women: A prospective population-based study. Osteoporos Int 1999 10 : 384 391.
81. Harper KD, Weber TJ. Secondary osteoporosis. Diagnostic considerations. Endocrinol Metab Clin North Am 1998 27 : 325 348.
82. Cakir B, Odabasi E, Turan M. Secondary osteoporosis in women. A retrospective analysis. Arch Gynecol Obstet 2002 266 : 214 217.
83. Grainge MJ, Coupland CA, Cliffe SJ et al. Cigarette smoking, alcohol and caffeine consumption, and bone mineral density in postmenopausal women. The Nottingham EPIC Study Group. Osteoporos Int 1998 8 : 355 363.
84. Ilich JZ, Brownbill RA, Tamborini L et al. To drink or not to drink: How are alcohol, caffeine and past smoking related to bone mineral density in elderly women? J Am Coll Nutr 2002 21 : 536 544.
85. Felson DT, Zhang Y, Hannan MT et al. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995 142 : 485 492.
86. Kanis JA, Delmas P, Burckhardt P et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997 7 : 390 406.
87. Bonaiuti D, Shea B, Iovine R et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002 (3) : CD000333.
88. Kelley GA. Aerobic exercise and bone density at the hip in postmenopausal women: A meta-analysis. Prev Med 1998 27 : 798 807.
89. Kelley GA. Exercise and regional bone mineral density in postmenopausal women: A meta-analytic review of randomized trials. Am J Phys Med Rehabil 1998 77 : 76 87.
90. Wolff I, van Croonenborg JJ, Kemper HC et al. The effect of exercise training programs on bone mass: A meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int 1999 9 : 1 12.
91. Wallace BA, Cumming RG. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int 2000 67 : 10 18.
92. Asikainen TM, Kukkonen-Harjula K, Miilunpalo S. Exercise for health for early postmenopausal women: A systematic review of randomised controlled trials. Sports Med 2004 34 : 753 778.
93. Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures research group. N Engl J Med 1995 332 : 767 773.
94. Orwoll ES, Bauer DC, Vogt TM et al. Axial bone mass in older women. Study of Osteoporotic Fractures research group. Ann Intern Med 1996 124 : 187 196.
95. Huuskonen J, Vaisanen SB, Kroger H et al. Regular physical exercise and bone mineral density a four-year controlled randomized trial in middle-aged men. The DNASCO Study. Osteoporos Int 2001 12 : 349 355.
96. Kanis J, Johnell O, Gullberg B et al. Risk factors for hip fracture in men from southern Europe: The MEDOS study. Mediterranean osteoporosis study. Osteoporos Int 1999 9 : 45 54.
97. Kujala UM, Kaprio J, Kannus P et al. Physical activity and osteoporotic hip fracture risk in men. Arch Intern Med 2000 160 : 705 708.
98. Bakhireva LN, Barrett-Connor E, Kritz-Silverstein D et al. Modifiable predictors of bone loss in older men: A prospective study. Am J Prev Med 2004 26 : 436 442.
99. Izumotani K, Hagiwara S, Izumotani T et al. Risk factors for osteoporosis in men. J Bone Miner Metab 2003 21 : 86 90.
100. Kohrt WM, Bloomfield SA, Little KD et al. American College of Sports Medicine position stand: Physical activity and bone health. Med Sci Sports Exerc 2004 36 : 1985 1996.
101. Prior JC, Barr SI, Chow R et al. Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis. Can Med Assoc J 1996 155 : 940 944.
102. Shea B, Wells G, Cranney A et al. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004 (1) : CD004526.
103. Prince RL, Devine A, Dhaliwal SS et al. Effects of calcium supplementation on clinical fracture and bone structure: Results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006 166 : 869 875.
104. Peacock M, Liu G, Carey M et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000 85 : 3011 3019.
105. Dawson-Hughes B, Harris SS, Krall EA et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997 337 : 670 676.
106. Orwoll ES, Oviatt SK, McClung MR et al. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 1990 112 : 29 34.
107. Grant AM, Avenell A, Campbell MK et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): Randomised placebo-controlled trial. Lancet 2005 365 : 1621 1628.
108. Avenell A, Gillespie WJ, Gillespie LD et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005 (3) : CD000227.
109. Papadimitropoulos E, Wells G, Shea B et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002 23 : 560 569.
110. Bischoff-Ferrari HA, Willett WC, Wong JB et al. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 2005 293 : 2257 2264.
111. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992 327 : 1637 1642.
112. Meyer HE, Smedshaug GB, Kvaavik E et al. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002 17 : 709 715.
113. Lips P, Graafmans WC, Ooms ME et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996 124 : 400 406.
114. Krieg MA, Jacquet AF, Bremgartner M et al. Effect of supplementation with vitamin D3 and calcium on quantitative ultrasound of bone in elderly institutionalized women: A longitudinal study. Osteoporos Int 1999 9 : 483 488.
115. Cranney A, Wells G, Willan A et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002 23 : 508 516.
116. Papapoulos SE, Quandt SA, Liberman UA et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005 16 : 468 474.
117. Greenspan SL, Schneider DL, McClung MR et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002 136 : 742 746.
118. Bone HG, Greenspan SL, McKeever C et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/estrogen study group. J Clin Endocrinol Metab 2000 85 : 720 726.
119. Cranney A, Waldegger L, Zytaruk N et al. Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev 2003 (4) : CD004523.
120. Boonen S, McClung MR, Eastell R et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and olde: Implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004 52 : 1832 1839.
121. Sato Y, Kanoko T, Satoh K et al. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: A randomized controlled trial. Arch Intern Med 2005 165 : 1737 1742.
122. Rosen CJ, Hochberg MC, Bonnick SL et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 2005 20 : 141 151.
123. Cranney A, Welch V, Adachi JD et al. Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev 2001 (4) : CD003376.
124. Harris ST, Watts NB, Jackson RD et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 1993 95 : 557 567.
125. Heath DA, Bullivant BG, Boiven C et al. The effects of cyclical etidronate on early postmenopausal bone loss: An open, randomized controlled study. J Clin Densitom 2000 3 : 27 33.
126. Tanko LB, Felsenberg D, Czerwinski E et al. Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 2003 254 : 159 167.
127. Chesnut CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004 19 : 1241 1249.
128. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002 346 : 653 661.
129. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 344 : 1434 1441.
130. Lindsay R, Nieves J, Formica C et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997 350 : 550 555.
131. Body JJ, Gaich GA, Scheele WH et al. A randomized double-blind trial to compare the efficacy of teriparatide. J Clin Endocrinol Metab 2002 87 : 4528 4535.
132. Cranney A, Tugwell P, Zytaruk N et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002 23 : 540 551.
133. Cardona JM, Pastor E. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials. Osteoporos Int 1997 7 : 165 174.
134. Kanis JA, McCloskey EV. Effect of calcitonin on vertebral and other fractures. Q J Med 1999 92 : 143149.
135. Cranney A, Tugwell P, Zytaruk N et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002 23 : 524 528.
136. Schacter HM, Clifford TJ, Cranney A et al. Raloxifene for Primary and Secondary Prevention of Osteoporotic Fractures in Postmenopausal Women. A Systematic Review of Efficacy and Safety Evidence (Technology Report No. 50). Ottawa, Canada : Canadian Coordinating Office for Health Technology Assessment, 2005.
137. Stevenson M, Lloyd Jones M, De Nigris E et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005 9 : 1 160.
138. Lufkin EG, Whitaker MD, Nickelsen T et al. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Miner Res 1998 13 : 1747 1754.
139. Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992 117 : 1016 1037.
140. Wells G, Tugwell P, Shea B et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002 23 : 529 539.
141. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 2001 285 : 2891 2897.
142. Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 2003 290 : 1729 1738.
143. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 288 : 321 333.
144. Cauley JA, Black DM, Barrett-Connor E et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/progestin Replacement Study (HERS). Am J Med 2001 110 : 442 450.
145. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 2005 142 : 855 860.
146. Wathen CN, Feig DS, Feightner JW et al. Hormone replacement therapy for the primary prevention of chronic diseases: Recommendation statement from the Canadian Task Force on Preventive Health Care. Can Med Assoc J 2004 170 : 1535 1537.
147. Kenny AM, Prestwood KM, Gruman CA et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001 56A : M266 M272.
148. Wang C, Swerdloff RS, Iranmanesh A et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxford) 2001 54 : 739 750.
149. Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004 89 : 503 510.
150. Stanley HL, Schmitt BP, Poses RM et al. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991 39 : 766 771.
151. Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 1996 18 : 171 177.
152. Reid IR, Wattie DJ, Evans MC et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996 156 : 1173 1177.
153. Behre HM, Kliesch S, Leifke E et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997 82 : 2386 2390.
154. Szulc P, Claustrat B, Marchand F et al. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: The MINOS Study. J Clin Endocrinol Metab 2003 88 : 5240 5247.
155. Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999 84 : 1966 1972.
156. Eastell R, Boyle IT, Compston J et al. Management of male osteoporosis: Report of the UK consensus group. Q J Med 1998 91 : 71 92.
157. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000 343 : 604 610.
158. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab 2001 86 : 5252 5255.
159. Ringe JD, Dorst A, Faber H et al. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004 24 : 110 113.
160. Sato Y, Iwamoto J, Kanoko T et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2006 26 : 427 431.
161. Ringe JD, Faber H, Farahmand P et al. Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study. Rheumatol Int 2006 26 : 427 431.
162. Trovas GP, Lyritis GP, Galanos A et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: Effects on bone mineral density and bone markers. J Bone Miner Res 2002 17 : 521 527.
163. Toth E, Csupor E, Meszaros S et al. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures - an open label study. Bone 2005 36 : 47 51.
164. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide. J Bone Miner Res 2003 18 : 9 17.
165. Kaufman JM, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int 2005 16 : 510 516.
166. Finkelstein JS, Hayes A, Hunzelman JL et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003 349 : 1216 1226.